{
  "scenario_id": "pharma_drug_approval_q2_2026",
  "context": "Pharmaceutical company, 2000 employees, evaluating NDA submission for new oncology treatment",
  "stakeholders": {
    "requester": "Chief Medical Officer",
    "approvers": [
      "CEO",
      "Board of Directors",
      "FDA Liaison"
    ],
    "influencers": [
      "Clinical Development Team",
      "Regulatory Affairs",
      "Commercial Strategy"
    ]
  },
  "request": {
    "amount": "$150M submission budget",
    "purpose": "File New Drug Application for breakthrough cancer therapy",
    "urgency": "high",
    "justification": "Phase 3 trial shows 40% improvement in survival rates"
  },
  "decision_process": [
    {
      "stage": "data_review",
      "duration": "4 weeks",
      "activities": [
        "Clinical trial analysis",
        "Safety profile assessment",
        "Manufacturing validation"
      ],
      "outcome": "Data supports submission"
    },
    {
      "stage": "regulatory_strategy",
      "duration": "3 weeks",
      "activities": [
        "FDA meeting preparation",
        "Labeling strategy",
        "Post-marketing commitments"
      ],
      "outcome": "Accelerated approval pathway recommended"
    },
    {
      "stage": "executive_approval",
      "duration": "2 weeks",
      "activities": [
        "Board presentation",
        "Financial impact review",
        "Risk mitigation planning"
      ],
      "outcome": "Approved with priority review voucher utilization"
    }
  ],
  "business_impact": {
    "expected_revenue": "$500M first year",
    "market_share_gain": "25%",
    "risk_factors": [
      "Clinical trial setbacks",
      "Competitor approvals",
      "Pricing reimbursement challenges"
    ]
  }
}
